Investigating the Effect of 4-week Omega-3 Polyunsaturated Fatty Acid Supplementation on Inflammation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-09

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigate the in vivo effects of n-3 PUFA supplementation on inflammation, gene expression and epigenetic signatures.

Ex vivo stimulation of peripheral blood mononuclear cells (PBMCs) collected pre and post n-3 supplementation and measurement of it's effect on inflammation, gene expression and epigenetic signatures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation

NCT01078909

Cardiovascular Disease Inflammation

COMPLETED PHASE3

Effect of Combined Fatty Acid Supplementation and Eccentric Exercise Training on Exercise Performance

NCT03259412

Exercise-induced Inflammation

COMPLETED NA

Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation

NCT01813110

Inflammatory Responses

COMPLETED NA

Effects of Omega-3 Fatty Acids on Markers of Inflammation

NCT01129050

Obesity Hypertriglyceridemia Insulin Resistance +1 more

COMPLETED NA

Effects of Omega-3 Fatty Acids in Ambient Air Pollution Exposure in Healthy Adults

NCT02921048

Health Effects of Ambient Air Pollution

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Supplementation

Omega-3 Polyunsaturated Fatty Acids

Group Type EXPERIMENTAL

Omega-3 Polyunsaturated Fatty Acids Supplementation

Intervention Type DIETARY_SUPPLEMENT

28 days of a commercially available supplement. 4 capsules per day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omega-3 Polyunsaturated Fatty Acids Supplementation

28 days of a commercially available supplement. 4 capsules per day.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OmegaVia Pharmaceutical Grade Omega-3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males
* Aged between 18 and 30 years

Exclusion Criteria

* Females (Due to differences in cell membrane incorporation of n-3 PUFAs between the sexes and the testing schedule being unable to fit in with menstrual cycle, therefore altering the blood markers that are being measured).
* Aged below 18 or above 30.
* Body mass index (BMI; in kg/ m2), below 18 or above 30.
* Use of vitamin or fish oil supplements in the last 6 months.
* High habitual oily fish consumption (\<4 servings per month).
* Smoking.
* Changes in weight in the past 6 months (Dieting) or planning on changing dietary habits.
* Habitual use of anti-inflammatory drugs.
* Self-reported history of diabetes.
* History of heart disease, coagulation/bleeding disorders, metabolic disease or Serious allergy.
* Known to have blood-borne virus.
* Receipt of inoculations within 2 months of starting the study or the intention to receive such during the study.
* Donation of or intention to donate blood within 8 weeks of the first sample or at any point during the intervention.

Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes